vTv Therapeutics Inc.

NASDAQ:VTVT

Biotechnology

Healthcare
$16.23 +1.47%

+$0.50 today

Market cap
$64.17M
Beta
0.27
P/E (TTM)
128.7
EPS (TTM)
$0.27
52W Low $14.00High $44.00

Volume 0.02M

Average 0.05M

VTVT Account Payables

Amounts the company owes suppliers for goods and services received.

vTv Therapeutics Inc.NASDAQ: VTVT

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 62.8% from a year ago

Account payables stood at $6.82M at the end of Q1 FY2026, up 62.8% from a year earlier and up 502.6% from the prior quarter. Over 3 fiscal years it compounded at -22.8% a year.

Context

  • Account payables amounted to 6.9% of total assets at the end of Q1 FY2026, down 6.2 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +62.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.82M+502.6% QoQ
Last fiscal yearDec 2025
$1.13M+20.6% YoY
Year agoMar 2025
$4.19M+62.8% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.8%——
1 year+20.6%——
3-year CAGR-22.8%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
1.13M USD
Year-over-year change
+20.6%
4-year CAGR
-11.9%

Account Payables vs competitors

How VTVT compares with its peers on the latest reported figures

  • VTVT's Mar 2026 account payables of $6.82M is the 4th highest of the 9 companies compared; the peer median is $3.9M.
  • Its year-over-year change of +62.8% is the 3rd highest of 9, against a peer median of +14.7%.
  • Account payables amounts to 6.9% of total assets for VTVT, versus a peer median of 20.4%.
VTVT Competitors Peer median
Account Payables for VTVT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FBIOFortress Biotech, Inc.Mar 2026$14.14M -49.2%-37.1%4.0%
OSTXOS Therapies IncorporatedMar 2026$13.85M +757.1%+100.9%189.8%
OTLKOutlook Therapeutics, Inc.Mar 2026$13.64M +75.6%+42.9%62.3%
VTVTvTv Therapeutics Inc.Mar 2026$6.82M +62.8%-22.8%6.9%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$4.4M +2.0%+27.2%37.0%
INKTMiNK Therapeutics, Inc.Mar 2026$3.39M +27.4%-16.2%32.7%
SPRBSpruce Biosciences, Inc.Mar 2026$2.68M +42.8%-12.9%4.8%
HOWLWerewolf Therapeutics, Inc.Jun 2026$1.94M -30.1%-14.8%8.0%
GANXGain Therapeutics, Inc.Mar 2026$1.52M -29.5%-20.2%8.1%
Peer median (excluding VTVT) $3.9M+14.7%-13.9%20.4%

Competitors are the stored peer set for VTVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents13.42M12.13M9.45M36.75M88.93M
Short-term Investments00000
Net Receivables57K12.42M102K62K0
Inventory100K0000
Other Current Assets35K15K65K113K218K
Total Current Assets15.62M27.09M10.66M38.11M89.89M
Property, Plant & Equipment (Net)680K556K361K153K0
Goodwill00000
Intangible Assets00000
Long-term Investments9.17M5.59M000
Tax Assets00000
Other Non-current Assets00006K
Total Non-current Assets9.85M6.14M361K153K6K
Total Assets25.47M33.24M11.02M38.27M89.9M
Account Payables1.88M2.46M4.08M939K1.13M
Short-term Debt256K224K191K00
Tax Payables00000
Deferred Revenue35K17K17K00
Other Current Liabilities3.2M788K4.7M1.51M2.17M
Total Current Liabilities8.5M7.71M10.62M5.2M6.64M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)018.67M18.67M18.67M18.67M
Other Non-current Liabilities1.26M684K110K100K152K
Total Non-current Liabilities1.75M19.69M18.95M18.77M18.82M
Total Liabilities10.25M27.4M29.57M23.97M25.46M
Common Stock901K27K27K32K39K
Retained Earnings(248.83M)(265.52M)(281.04M)(299.72M)(326.69M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest24.96M16.58M6.13M2.1M0
Total Equity15.22M5.84M(18.55M)14.3M64.44M
Total Debt932K716K529K169K0
Net Debt(12.48M)(11.41M)(8.92M)(36.58M)(88.93M)

vTv Therapeutics Inc.

NASDAQ:VTVT

Intrinsic Alpha fair value

Locked

Current Price

$16.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.